Trajan congratulates Kinesis on Queen's Award for Enterprise in International Trade

Trajan congratulates Kinesis on Queen's Award for Enterprise in International Trade

December 08, 2016

Trajan Scientific and Medical (Trajan) congratulates and celebrates with Kinesis, on winning the Queen’s Award for Enterprise in International Trade 2016. Kinesis is a key international distributor of Trajan's range of analytical products.

From Kinesis:

This year, Kinesis was delighted to be named a winner of the UK’s highest accolade for business success – The Queen’s Award for Enterprise in International Trade 2016. The award was made in recognition of Kinesis achieving continuous growth in export sales over the last six years of the business.

At Kinesis, we understand that this award, just like our continued growth in the business, could not have been made possible without the ongoing support of our most valued suppliers and partners. It was therefore with great pleasure that we presented our key partners with a special Appreciation Award in recognition of their ongoing positive contribution to our company’s success.

Jamie Gallifant, Group Managing Director remarked: “We are delighted and honoured to have won this prestigious award, this success is directly attributable to the efforts of all within the Kinesis Group. We’d particularly like to recognise the long term support of our customers and supply partners. This is an important stage in our company development and we will strive to continue to offer unrivalled service and support to our global customer base. As our most valued suppliers, we would like to genuinely thank you for the support you have provided to Kinesis over the past years. Receiving this Award was only made possible due to the successful partnership between Kinesis and your respective companies.  We have ambitious plans for the future and we look forward to continued close collaboration between our companies to achieve further growth.

Read the full article at Kinesis website: Kinesis celebrates Queen’s Awards win with valued suppliers

Mr Gary Thomas, International Sales Manager, Kinesis, and Mr Andy Hall, EMEA Operations and Distribution Manager, Trajan, at Trajan's Global Commercial Office, Chester, UK.
Photo: Mr Gary Thomas, International Sales Manager, Kinesis, and Mr Andy Hall, EMEA Operations and Distribution Manager, Trajan, at Trajan's Global Commercial Office, Chester, UK.

More information
Kinesis celebrates winning the Queen’s Awards for Enterprise: International Trade 2016
Kinesis feature in the 2016 Queen's Award Magazine

Media contact information
Trajan Scientific and Medical
media@trajanscimed.com
44 (0) 1244 403 100




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More